Latest Breaking News On - Hd immune gmbh hdi biotechnology antibody treatments huntingtons disease stefan bartl lionel wightman affiris ag austria wirtschafts service austrian centre of industrial neurodegenerative monogenetic disorder mutant huntingtin protein mthtt preclinical data preseed financing round institute molecular - Page 1 : comparemela.com
HD Immune GmbH HDI a privately held biotechnology company developing novel antibody treatments for Huntingtons Disease announces commencement of operations by its two founders Dr. Stefan Bartl and Dr. Lionel Wightman.